Skip to content

Breast Cancer Health Center

Herceptin: Long-Term Benefits for Breast Cancer

Study Shows Drug May Still Help Breast Cancer Patients Years After Ending Treatment
Font Size
A
A
A
By
WebMD Health News
Reviewed by Laura J. Martin, MD

Feb. 24, 2011 -- High-risk breast cancer patients continue to derive benefits from the drug Herceptin even four years after stopping treatment, but questions remain about the biologic therapy’s safety when given with chemotherapy.

Newly reported follow-up data from a large international study show that women with early-stage HER2-positive breast tumors who took Herceptin for one year are 24% less likely to have their tumors return after four years than women who did not take the drug.

Overall survival was no better for patients treated with the biologic therapy than for patients who received chemotherapy alone. But researchers attribute this to the fact that women who originally did not take the drug were allowed to cross over into the active-treatment part of the study based on the strength of the early findings.

About one in five breast cancers are HER2 positive, which tend to be more aggressive and difficult to treat than other breast cancers.

4-Year Outcomes Still Encouraging

The Herceptin Adjuvant (HERA) international study included more than 5,000 women with HER2-positive, early-stage breast cancers enrolled between December 2001 and June 2005.

The original study design called for the women to receive either standard chemotherapy alone, chemotherapy followed by one year of Herceptin, or chemotherapy followed by two years on the biologic drug.

One-year follow-up data from the study, reported in 2005, show an almost 50% reduction in disease recurrences in women treated with the drug for a year.

The latest findings confirm that treatment with Herceptin following chemotherapy has long-term benefits for women with early stage HER2-positive tumors, says study researcher Luca Gianni, MD, of Milan Italy’s San Raffaele Institute.

He adds that findings from the two-year treatment part of the study should be reported later this year or early next year.

The latest results from the ongoing study are published in the Feb. 25 issue of The Lancet.

“We can’t say this yet, but it may be that treatment for longer than one year is optimal,” Gianni tells WebMD.

Questions Remain About Treatment Timing

Breast cancer specialist Edith Perez, MD, of the Mayo Clinic Florida, says it remains to be seen if treatment longer or shorter than a year is optimal.

Today on WebMD

Breast Cancer Overview
From self-exams and biopsies to reconstruction, we’ve got you covered.
Dealing with breast cancer
Get answers to your questions.
 
woman having mammogram
Experts don’t agree on all fronts, but you can be your own advocate.
woman undergoing breast cancer test
Many women worry. But the truth? Most abnormalities aren’t breast cancer.
 
Breast Cancer Treatments Improving
VIDEO
Resolved To Quit Smoking
SLIDESHOW
 
Woman getting mammogram
Article
Screening Tests for Women
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
serious woman
Article
 
what is your cancer risk
HEALTH CHECK
10 Ways to Revitalize Slideshow
SLIDESHOW